Re-evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients

Internal Medicine

Volumn 49, Issue 6, 2010, Pages 525-528

  Yagura, Michiyasu ^a   Tanaka, Akihisa ^a   Kamitsukasa, Hiroshi ^a   Otsuka, Hiroki ^b   Kanno, Sotaro ^b   Aoyama, Toshihisa ^c  

^a TOKYO NATIONAL HOSPITAL   (Japan)

^b The Center of Health Promotion   (Japan)

^c Sekishinkai Sayama Hospital   (Japan)

Author keywords

Chronic hepatitis C; Healthy volunteers; Interferon; Sustained virological response; Upper limit of the normal range for serum ALT

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ANALYSIS; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PATIENT ASSESSMENT; TREATMENT DURATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; REFERENCE VALUES;

EID: 77950651376     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2653     Document Type: Article

References (14)

1. Hadziyannis SJ, Settee H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
2. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47: 43-50, 2008.
3. Karmen A, Wroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 34: 126-133, 1955.
4. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137: 1-9, 2002.
5. Hay JE, Czaya AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevation of a mild to moderate degree in asymptomatic patients. Hepatology 9: 193-197, 1989.
6. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94: 3010-3045, 1999.
7. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342: 1266-1271, 2000.
8. Zanella A, Conte D, Prati D, et al. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay. Hepatology 21: 913-917, 1995.
9. Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 110: 178-183, 1996.
10. Alberti A, Morsica G, Chemollo L, et al. Hepatitis C viremia and liver disease in symptom-free individuals with anti-HCV. Lancet 340: 697-698, 1992.
11. Corny-Cantilena C, Van Aden M, Gabble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334: 1691-1696, 1996.
12. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362, 1999.
13. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis. MULTIVIRC Group. Hepatology 27: 1213-1219, 1998.
14. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransaminase activity in the United States population. Gastroenterology 124: 71-79, 2003.